BRPI0811065A2 - 5-HETEROARYL INDAZOES REPLACED AS KINASE INHIBITORS - Google Patents

5-HETEROARYL INDAZOES REPLACED AS KINASE INHIBITORS

Info

Publication number
BRPI0811065A2
BRPI0811065A2 BRPI0811065-4A2A BRPI0811065A BRPI0811065A2 BR PI0811065 A2 BRPI0811065 A2 BR PI0811065A2 BR PI0811065 A BRPI0811065 A BR PI0811065A BR PI0811065 A2 BRPI0811065 A2 BR PI0811065A2
Authority
BR
Brazil
Prior art keywords
indazoes
heteroaryl
replaced
kinase inhibitors
kinase
Prior art date
Application number
BRPI0811065-4A2A
Other languages
Portuguese (pt)
Inventor
Irini Akritopoulou-Zanze
Brian D Wakefield
Helmut Mack
Sean C Turner
Alan F Gasiecki
Vijava J Gracias
Kathy Sarris
Douglas M Kalvin
Melissa J Michmerhuizen
Qi Shuai
Jyoti R Patel
Margaretha Bakker
Nicole Teusch
Eric F Johnson
Peter J Kovar
Stevan W Djuric
Andrew J Long
Anil Vasudevan
Adrian Hobson
Nigel St John Moore
Lu Wang
Dawn George
Biqin Li
Kristine Frank
Original Assignee
Abbott Lab
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab, Abbott Gmbh & Co Kg filed Critical Abbott Lab
Publication of BRPI0811065A2 publication Critical patent/BRPI0811065A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
BRPI0811065-4A2A 2007-06-08 2008-06-04 5-HETEROARYL INDAZOES REPLACED AS KINASE INHIBITORS BRPI0811065A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93396007P 2007-06-08 2007-06-08
PCT/US2008/065727 WO2008154241A1 (en) 2007-06-08 2008-06-04 5-heteroaryl substituted indazoles as kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0811065A2 true BRPI0811065A2 (en) 2014-12-02

Family

ID=39951673

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0811065-4A2A BRPI0811065A2 (en) 2007-06-08 2008-06-04 5-HETEROARYL INDAZOES REPLACED AS KINASE INHIBITORS

Country Status (13)

Country Link
EP (1) EP2167491A1 (en)
JP (2) JP5451602B2 (en)
KR (1) KR20100032886A (en)
CN (1) CN101790526A (en)
AU (1) AU2008262038A1 (en)
BR (1) BRPI0811065A2 (en)
CA (1) CA2689117A1 (en)
IL (1) IL202318A0 (en)
MX (1) MX2009013213A (en)
RU (1) RU2487873C2 (en)
SG (1) SG182187A1 (en)
WO (1) WO2008154241A1 (en)
ZA (1) ZA200908624B (en)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
JP2009528280A (en) 2006-02-16 2009-08-06 シェーリング コーポレイション Pyrrolidine derivatives as ERK inhibitors
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
WO2008156757A1 (en) * 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
EP2173728A2 (en) 2007-07-17 2010-04-14 Amgen Inc. Heterocyclic modulators of pkb
US7919504B2 (en) 2007-07-17 2011-04-05 Amgen Inc. Thiadiazole modulators of PKB
JPWO2009028543A1 (en) * 2007-08-30 2010-12-02 武田薬品工業株式会社 Substituted pyrazole derivatives
US8716483B2 (en) 2008-02-21 2014-05-06 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
CL2009001158A1 (en) 2008-05-15 2009-10-23 Nerviano Medical Sciences Srl Compounds derived from carboxylic acids, such as 5,6-dihiro-4h-pyrrolo [3,4-c] pyrazole, furo [3,2-c] pyrazole, thieno [2,3-c] pyrazole, 4,5 , 6,7-tetrahydropyrazole [4,3-c] pyridine and indazole; pharmaceutical composition; and its use in the treatment of cell proliferative disorders associated with altered protein kinase activity, such as cancer.
AR074199A1 (en) * 2008-11-20 2010-12-29 Glaxosmithkline Llc COMPOSITE OF 6- (4-PYRIMIDINYL) -1H-INDAZOL, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE IT AND ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OR DECREASE OF CANCER GRAVITY.
CN105037355B (en) 2009-08-10 2017-06-06 萨穆梅德有限公司 The indazole inhibitors and its therapeutical uses of Wnt signal transduction paths
LT3001903T (en) 2009-12-21 2018-01-10 Samumed, Llc 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
UY33213A (en) * 2010-02-18 2011-09-30 Almirall Sa PIRAZOL DERIVATIVES AS JAK INHIBITORS
KR101233082B1 (en) 2010-02-25 2013-02-14 주식회사 이큐스앤자루 A composition containing of novel imidazole pyrazine compound having Influenza virus activity for treating antivirus
JP6026284B2 (en) * 2010-03-03 2016-11-16 プロビオドルグ エージー Inhibitors of glutaminyl cyclase
KR20130065632A (en) * 2010-04-28 2013-06-19 다이이찌 산쿄 가부시키가이샤 [5,6]heterocyclic compound
EP2566333A4 (en) * 2010-05-07 2014-04-02 Univ Leland Stanford Junior IDENTIFICATION OF MULTIMERIC PROTEIN STABILIZERS
BR112013015460B1 (en) * 2010-12-20 2022-01-25 Merck Serono S.A. Indazolyl triazole derivatives, kit, and pharmaceutical composition
CA2822357A1 (en) 2010-12-22 2012-06-28 Abbvie Inc. Hepatitis c inhibitors and uses thereof
US9090592B2 (en) * 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
CN102675286B (en) * 2011-03-07 2015-08-19 中国科学院上海药物研究所 Indazole compounds, preparation method, application and pharmaceutical composition thereof
HUE026323T2 (en) * 2011-04-07 2016-05-30 Bayer Ip Gmbh Imidazopyridazines as AKT kinase inhibitors
EP2742046A1 (en) * 2011-08-12 2014-06-18 F.Hoffmann-La Roche Ag PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE
IN2014CN02646A (en) 2011-09-14 2015-08-07 Samumed Llc
DK2921493T3 (en) 2011-12-27 2017-11-27 Bayer Ip Gmbh HETEROARYLPIPERIDINE AND ¿PIPERAZINE DERIVATIVES
AU2013224302B2 (en) * 2012-02-21 2017-03-30 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
NZ629282A (en) 2012-05-04 2017-04-28 Samumed Llc 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
TW201406758A (en) * 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd Tricyclic compounds
EP2943198B1 (en) 2013-01-08 2019-07-17 Samumed, LLC 3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof
WO2014134772A1 (en) * 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014137728A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134776A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134774A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
JO3383B1 (en) * 2013-03-14 2019-03-13 Lilly Co Eli CDC7 Inhibitors
JP6461118B2 (en) * 2013-06-21 2019-01-30 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． Novel substituted bicyclic compounds as bromodomain inhibitors
JP6602779B2 (en) 2014-02-13 2019-11-06 インサイト・コーポレイション Cyclopropylamines as LSD1 inhibitors
EP3105218B1 (en) 2014-02-13 2019-09-25 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
EP3105219B9 (en) 2014-02-13 2018-10-03 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
CN106535890A (en) 2014-03-20 2017-03-22 萨穆梅德有限公司 5-substituted indazole-3-carboxamides and preparation and use thereof
WO2015143652A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
BR112016026951B1 (en) * 2014-06-25 2022-09-20 F. Hoffmann-La Roche Ag IMIDAZO[1,2-A]PIRAZIN-1-IL-BENZAMIDE, ITS USE, AND PHARMACEUTICAL COMPOSITIONS
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
WO2016025129A1 (en) 2014-08-14 2016-02-18 Alhamadsheh Mamoun M Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040182A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040188A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040190A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
EA037112B1 (en) 2015-03-02 2021-02-08 Ригель Фармасьютикалс, Инк. Tgf- inhibitors
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
US10226453B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10463651B2 (en) 2015-08-03 2019-11-05 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof
WO2017024003A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023986A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof
US10350199B2 (en) 2015-08-03 2019-07-16 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
US10166218B2 (en) 2015-08-03 2019-01-01 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017023996A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
WO2017023980A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10383861B2 (en) 2015-08-03 2019-08-20 Sammumed, LLC 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017023987A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
WO2017023989A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017024004A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10329309B2 (en) 2015-08-03 2019-06-25 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023972A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10519169B2 (en) 2015-08-03 2019-12-31 Samumed, Llc 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023988A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023984A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
MY189367A (en) 2015-08-12 2022-02-08 Incyte Corp Salts of an lsd1 inhibitor
MX380092B (en) 2015-11-06 2025-03-11 Samumed Llc TREATMENT OF OSTEOARTHRITIS.
US20170273307A1 (en) * 2016-03-28 2017-09-28 Trent University Silane-based antimicrobial coatings and methods of making and using the same
TWI833686B (en) 2016-04-22 2024-03-01 美商英塞特公司 Formulations of an lsd1 inhibitor
AR108325A1 (en) 2016-04-27 2018-08-08 Samumed Llc ISOQUINOLIN-3-IL CARBOXAMIDS AND PREPARATION AND USE OF THE SAME
MX390577B (en) 2016-06-01 2025-03-20 Samumed Llc Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
RU2752088C1 (en) * 2016-09-21 2021-07-22 Вектус Байосистемс Лимитед Compositions for treatment of hypertension and/or fibrosis
JOP20190053A1 (en) 2016-09-23 2019-03-21 Novartis Ag Aza-indazole compounds for use in tendon and/or ligament injuries
RU2749547C2 (en) 2016-09-23 2021-06-15 Новартис Аг Indazole compounds for use in tendon and/or ligament injuries
JP2019535672A (en) 2016-10-21 2019-12-12 サミュメッド リミテッド ライアビリティ カンパニー Methods of using indazole-3-carboxamides and their use as inhibitors of WNT / Β-catenin signaling pathway
MA46696A (en) 2016-11-07 2019-09-11 Samumed Llc READY-TO-USE SINGLE-DOSE INJECTABLE FORMULATIONS
BR112019011200B1 (en) * 2016-12-01 2021-12-28 Arvinas Operations, Inc TETRAHYDRONAPPHTALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADATORS
CN116730920A (en) 2017-02-17 2023-09-12 文涵治疗有限公司 AG-10 preparation method, intermediate and salt thereof
JP7311228B2 (en) 2017-06-30 2023-07-19 ベイジン タイド ファーマシューティカル カンパニー リミテッド RHO-related protein kinase inhibitors, pharmaceutical compositions containing same and methods for preparation and use thereof
KR102563325B1 (en) * 2017-06-30 2023-08-03 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 ROH-related protein kinase inhibitors, pharmaceutical compositions containing RS-related protein kinase inhibitors, manufacturing methods and uses of pharmaceutical compositions
AU2019222758B2 (en) 2018-02-15 2022-07-07 Vertex Pharmaceuticals Incorporated Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cystic fibrosis, and process for making them
TWI817999B (en) 2018-03-23 2023-10-11 美商文涵治療有限公司 Methods of treating ttr amyloidosis using ag10
US11345678B2 (en) * 2018-04-18 2022-05-31 Medshine Discovery Inc. Benzopyrazole compound used as RHO kinase inhibitor
SI3836920T1 (en) 2018-08-17 2026-02-27 Eidos Therapeutics, Inc. AG10 formulations
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
CN111138426B (en) * 2018-11-02 2023-03-10 安徽中科拓苒药物科学研究有限公司 Indazole kinase inhibitor and application thereof
EP3920885A1 (en) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
TWI848092B (en) 2019-04-03 2024-07-11 美商維泰克斯製藥公司 Cystic fibrosis transmembrane conductance regulator modulating agents
CN110218694A (en) * 2019-05-30 2019-09-10 华中农业大学 A kind of kiwifruit fruit amyloplaste extracting method
TWI867024B (en) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 Modulators of cystic fibrosis transmembrane conductance regulator
CA3150162A1 (en) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
TWI899097B (en) 2019-08-14 2025-10-01 美商維泰克斯製藥公司 Process of making cftr modulators
KR20220054347A (en) 2019-08-26 2022-05-02 아비나스 오퍼레이션스, 인코포레이티드 Method of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
CN111171023B (en) * 2020-01-10 2021-12-21 中国药科大学 Compound with Pim1 inhibitory activity and preparation method and medical application thereof
CN113350347B (en) * 2020-03-05 2023-07-04 安徽中科拓苒药物科学研究有限公司 Use of indazoles
JP2023540674A (en) * 2020-07-15 2023-09-26 アイエフエム デュー インコーポレイテッド Compounds and compositions for treating conditions associated with STING activity
WO2022056368A1 (en) 2020-09-14 2022-03-17 Arvinas Operations, Inc. Crystalline forms of a compound for the targeted degradation of estrogen receptor
WO2022076629A1 (en) * 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CN112266378B (en) * 2020-11-09 2021-10-12 延边大学 Imidazole derivative containing indazole structure and preparation method and application thereof
AU2021397294A1 (en) 2020-12-10 2023-07-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN113336759B (en) * 2020-12-25 2022-12-06 中国药科大学 Bromodomain protein 4 small molecule inhibitor, preparation method and application thereof
EP4274824A1 (en) * 2021-01-08 2023-11-15 IFM Due, Inc. Heterobicyclic compounds having an urea or analogue and their compositions for treating conditions associated with sting activity
BR112023025403A2 (en) 2021-06-25 2024-02-20 Korea Res Inst Chemical Tech BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING FUNCTION OF BTK DEGRADATION THROUGH THE UBIQUITIN PROTEASOMA PATHWAY AND USE OF THE SAME
IL310724A (en) 2021-08-10 2024-04-01 Ifm Due Inc Compounds and compositions for treating conditions associated with sting activity
KR20230056824A (en) * 2021-10-20 2023-04-28 전북대학교산학협력단 PAK4 inhibitors and use thereof
CN118974020A (en) 2022-03-30 2024-11-15 内尔维亚诺医疗科学公司 Substituted 3-aminoindazole derivatives as kinase inhibitors
CN114651898B (en) * 2022-03-31 2024-04-05 天津溢佳同惠科技集团有限公司 Triazole feed additive for improving immunity as well as preparation method and application thereof
WO2023218201A1 (en) * 2022-05-11 2023-11-16 Cancer Research Technology Limited Ikk inhibitors
KR102607237B1 (en) * 2023-06-07 2023-11-30 주식회사 젠센 New triazole substituted indazole derivatives and use thereof
CN116891460A (en) * 2023-07-12 2023-10-17 浙江大学 An indazole derivative or its medicinal salt and application
WO2026005530A1 (en) * 2024-06-27 2026-01-02 전북대학교산학협력단 Novel compound and pharmaceutical use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU54202A (en) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Indazole compounds,pharmaceutical compositions,and methods for mediating or inhibiting cell proliferation
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US20040102455A1 (en) * 2001-01-30 2004-05-27 Burns Christopher John Method of inhibiting kinases
CN1319968C (en) * 2002-08-02 2007-06-06 沃泰克斯药物股份有限公司 Pyrazole compositions useful as inhibitors of GSK-3
GB2391557A (en) * 2002-08-06 2004-02-11 Richard Stone Forming fabric for papermaking
FR2845382A1 (en) * 2002-10-02 2004-04-09 Sanofi Synthelabo INDAZOLECARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS
US20040087642A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
BR0316606A (en) * 2002-12-12 2005-10-11 Aventis Pharma Sa Aminoindazole derivatives and their use as kinase inhibitors
US7008953B2 (en) * 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US20050090529A1 (en) * 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
JP2007519753A (en) * 2004-01-30 2007-07-19 スミスクライン ビーチャム コーポレーション Compound
FR2867778B1 (en) * 2004-03-16 2006-06-09 Sanofi Synthelabo USE OF INDAZOLECARBOXAMIDE DERIVATIVES FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT AND PREVENTION OF MALARIA
CA2567977A1 (en) * 2004-04-22 2006-01-05 Memory Pharmaceutical Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
US7429604B2 (en) * 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
DE102004028862A1 (en) * 2004-06-15 2005-12-29 Merck Patent Gmbh 3-aminoindazoles
US20050282818A1 (en) * 2004-06-22 2005-12-22 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
MX2007007797A (en) * 2004-12-27 2007-08-23 Alcon Inc Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases.
CA2606110A1 (en) * 2005-04-29 2006-12-07 Celgene Corporation Solid forms of 1-(5-(1h-1,2,4-triazol-5-yl)(1h-indazol-3-yl))-3-(2-piperidylethoxy)benzene
TW200803863A (en) * 2005-11-10 2008-01-16 Schering Corp Method for inhibiting protein kinases
CA2644910C (en) * 2006-03-31 2014-01-28 Abbott Laboratories Indazole compounds

Also Published As

Publication number Publication date
EP2167491A1 (en) 2010-03-31
MX2009013213A (en) 2010-03-30
RU2009149696A (en) 2011-07-20
ZA200908624B (en) 2015-08-26
KR20100032886A (en) 2010-03-26
CA2689117A1 (en) 2008-12-18
SG182187A1 (en) 2012-07-30
JP2014074057A (en) 2014-04-24
WO2008154241A1 (en) 2008-12-18
IL202318A0 (en) 2010-06-30
JP2010529137A (en) 2010-08-26
CN101790526A (en) 2010-07-28
AU2008262038A1 (en) 2008-12-18
RU2487873C2 (en) 2013-07-20
JP5451602B2 (en) 2014-03-26

Similar Documents

Publication Publication Date Title
BRPI0811065A2 (en) 5-HETEROARYL INDAZOES REPLACED AS KINASE INHIBITORS
CY2019027I2 (en) PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS
BRPI0913879A2 (en) phenylpyrazinones as kinase inhibitors
BRPI0920135A2 (en) imidazopyridazinecarbonitriles useful as kinase inhibitors
BRPI0812825A2 (en) FTAAZINONE DERIVATIVES AS PARP-1 INHIBITORS
BRPI0913580A2 (en) pyrrolopyridines as kinase inhibitors
BRPI0918846A2 (en) heterocyclic kinase inhibitors
BRPI0912475A2 (en) compounds as kinase inhibitors
BRPI0906973A2 (en) Compounds and compositions as kinase inhibitors.
BRPI0914652A2 (en) compounds and compositions as kinase inhibitors
EP2376493A4 (en) DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE
DK2308877T3 (en) Imidazopyridine-2-one derivatives
EP2380877A4 (en) PYRIDINE-3-CARBOXYAMIDE DERIVATIVE
DK2285786T3 (en) Quinoxalinedione DERIVATIVES
BRPI0906838A2 (en) Pyrimidines as kinase inhibitors
BRPI0920239A2 (en) heterocyclic compounds as protein kinase inhibitors
BRPI0922880A2 (en) kinase inhibitor compounds
SMT201600045B (en) C7-FLUORO REPLACED TETRACYCLINIC COMPOUNDS
BRPI0913832A2 (en) pyrrolopyridinylpyrimidin-2-ylamine derivatives
BRPI0906705A2 (en) Heterocyclic Compounds
EP2336132A4 (en) MORPHOLINOPURIN DERIVATIVE
DE112009000578A5 (en) reamer
BRPI0918564A2 (en) inhibitors
BRPI0910979A2 (en) compounds and compositions as kinase inhibitors
BRPI0914545A2 (en) compounds and compositions as kinase inhibitors

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ABBOTT GMBH AND CO. KG (DE) , ABBVIE INC. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.